Dartmouth College

Io Therapeutics, Inc.

King's College London

University of Massachusetts

Bristol-myers Squibb Compnay

Other

3m Innovative Properties Company

Immurx, Inc.

Nederlandse Organisatie Voor Toegepast-natuurwetenschappelijk Onderzoek Tno

Darmouth College

Lo Therapeutics, Inc.

Wang, Li

Green, Kathy A.

Green, William R.

Noelle, Randolph J.

Randolph J Noelle

Elizabeth Nowak

Roshantha A Chandraratna

Ethan Dmitrovsky

Cory L Ahonen

Li Wang

Teresa M Foy

Isabelle Lemercier

Sabrina Ceeraz

Janet Lines

Fiona H Durie

Jeffrey A Ledbetter

Alejandro A Aruffo

Ross M Kedl

Aldo A Rossini

John P Mordes

David C Parker

Mark R Spaller

Nancy E Phillips

Dale L Grenier

Michael C Appel

Li-Fan Lu

Martin E Sanders

Sergio Quezada

David Gondek

Lili Wang

Ivan Stamenkovic

Eric Claassen

Dale L Greiner

William R Green

Kathy A Green

Janet Louise Lines

Mark Spaller

The present specification provides RXR agonists with both remyelination promotion and immunomodulatory activities, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat a demyelination-related disorder by both promoting remyelination of neurons and modulating the immune system.

Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists

The present invention relates to a fusion proteins comprising regulatory T cell protein, VISTA (V-domain Immunoglobulin Suppressor of T cell Activation (PD-L3) and an immunoglobulin protein (Ig), preferably also containing a flexible linker intervening the VISTA and Ig Fc polypeptide. The invention also provides the use of VISTA polypeptides, multimeric VISTA polypeptides, VISTA-conjugates (e.g., VISTA-Ig), and VISTA antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions, especially lupus, multiple sclerosis, psoriasis, psoriatic arthritis, multiple sclerosis, Crohn's disease, inflammatory bowel disease and type 1 or type 2 diabetes.

VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders

The present invention relates to a fusion proteins comprising regulatory T cell protein, VISTA (V-domain Immunoglobulin Suppressor of T cell Activation (PD-L3) and an immunoglobulin protein (Ig). The invention also provides the use of VISTA polypeptides, multimeric VISTA polypeptides, VISTA-conjugates (e.g., VISTA-Ig), and VISTA antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions.

VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders

The present invention is directed to a peptide, multimer, conjugate, analog, derivative or mimetic thereof that inhibits the activity of VISTA. The invention further contemplates therapeutic use of the VISTA antagonist peptide, multimer, conjugate, derivative or mimetic thereof, including treating or preventing cancer, bacterial infections, viral infections, parasitic infections and fungal infections, as well as research uses of the antagonist.

Vista antagonist and methods of use

The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.

Autoimmune disorder treatment using RXR agonists

Improved anti-CD154 antibodies are provided herein which have ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein.

Nucleic acids encoding an anti-CD154 antibody comprising E269R and K322A mutations

The present disclosure relates to compositions and therapeutic methods for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are able to antagonize the activity of VISTA, a naturally occurring 'checkpoint' protein which contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pathway such as PD-1. For example, such methods and compositions may be suitable for preventing and treating colon cancer or another cancer. An exemplary VISTA antagonist, specifically, an anti-VISTA antibody, is demonstrated herein to activate an immune response against cancer cells in vitro and in vivo, thereby conferring protective anti-tumor immunity which decreased tumor burden. Additionally, an additive benefit was observed when a VISTA antagonist was used in combination with a second checkpoint protein antagonist, specifically, an antibody against PD-1 ligand (PD-L1).

Vista modulators for diagnosis and treatment of cancer

The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates &#x3b1;CD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon &#x3b1;CD3/&#x3b1;GITR stimulation. This protein has been designated T-sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed. In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g. multiple sclerosis is disclosed.

Regulatory T cell mediator proteins and uses thereof

Methods for alleviating the suppression of humoral immunity by myeloid-dependent suppressor cells (MDSCs) are provided which include the administration of a VISTA antagonist and an iNOS/NO inhibitor in a subject in need thereof, e.g., subjects with cancer or infectious disease wherein VISTA is aberrantly expressed. This combination has been discovered to elicit a synergistic or additive effect on alleviating suppression of humoral immunity by VISTA which is elicited by MDSCs.

Use of vista agonists and antagonists to suppress or enhance humoral immunity

Growing community of inventors

Plainfield, NH, United States of America

Randolph J Noelle